FDA Renews Crackdown on GLP-1 Compounders (NVO:NYSE)

FDA renews crackdown on GLP-1 compounders (NVO:NYSE)

Novo Nordisk (NVO) stock and Eli Lilly (LLY) stock are in focus as the FDA warns telehealth firms about making false claims on compounded GLP-1 drugs. Read more here.

FDA Warns Telehealth Companies Against Misleading Claims on Compounded Weight-Loss Drugs

The U.S. Food and Drug Administration (FDA) on June 16 issued a series of warning letters to telehealth companies for promoting compounded weight-loss and diabetes drugs with “false and misleading” claims. The agency said it had sent 25 warning letters to telehealth companies such as Ready Med, Maximus Health, and Medica Weight Loss over claims that their compounded GLP-1 drugs had been evaluated for safety. “Unlike FDA-approved drugs, these pro…

FDA warns telehealth companies over compounded GLP-1s

The FDA has issued a new batch of warning letters to 25 telehealth companies, accusing them of making false and misleading claims in their marketing of compounded GLP-1 weight loss drugs. The letters, issued earlier ...